FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:298-300 January 19, 2006 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lieberman, J. A. PubMed Citation

To the Editor: The report by Lieberman and colleagues (Sept. 22 issue)¹ on the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE), funded by the National Institute of Mental Health, raises some questions that require clarification. One can see from the results that olanzapine and perphenazine, which were superior with respect to the rate of discontinuation of treatment, were given in rather high doses, as compared with the doses used in an observational study.² In contrast, the antipsychotic drugs that were discontinued mainly because of a lack of efficacy, quetiapine and ziprasidone, were given in doses that were rather low (for . . . [Full Text of this Article]

This article has been cited by other articles:

• Rabinowitz, J., Davidov, O. (2008). A Composite Approach That Includes Dropout Rates When Analyzing Efficacy Data in Clinical Trials of Antipsychotic Medications. Schizophr Bull 34: 1145-1150 [Abstract] [Full Text]  
• Rabinowitz, J., Davidov, O. (2008). The Association of Dropout and Outcome in Trials of Antipsychotic Medication and Its Implications for Dealing With Missing Data. Schizophr Bull 34: 286-291 [Abstract] [Full Text]  
• Heres, S., Kissling, W., Leucht, S. (2007). Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia. Evid. Based Ment. Health 10: 112-112 [Full Text]